Frontier Capital Management Co. LLC Sells 4,735 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Frontier Capital Management Co. LLC trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 35,562 shares of the biotechnology company’s stock after selling 4,735 shares during the period. Frontier Capital Management Co. LLC’s holdings in Sarepta Therapeutics were worth $4,324,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SRPT. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $36,000. Steward Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 216 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Trading Down 0.7 %

Shares of NASDAQ:SRPT opened at $36.27 on Friday. The stock’s 50-day simple moving average is $66.84 and its two-hundred day simple moving average is $100.86. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 52-week low of $35.46 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the firm posted $0.73 earnings per share. The business’s quarterly revenue was up 80.2% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SRPT shares. Needham & Company LLC cut their price objective on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday. Piper Sandler lowered their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday. Evercore ISI cut Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price on the stock. in a research note on Thursday. Wells Fargo & Company lowered their price target on Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating on the stock in a research report on Wednesday. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.22.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.